They assessed the effect of Gefitinib on CSCs and non-CSCs, which were separated by CD133 antibody from NSCLC cell line PC9 cells expressing the EGFR exon 19 deletion mutation and sensitive to Gefinitib. The gene discussed is PROM1; the disease is non-small cell lung carcinoma.